Advertisement
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line
(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.
Charles River Research Models & Services (RMS) sales and marketing teams will collaborate with DURECT to jointly market and commercialize the ALZET product line to existing and new customers over a multi-year period.
Charles River RMS will provide dedicated marketing resources and collaborate with DURECT to develop and roll out a broad range of sales and marketing initiatives for ALZET.
DURECT will remain responsible for manufacturing, marketing support, order fulfillment and customer billing.
read more
Charles River Laboratories Slashes FY24 Outlook - Update
While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews
|
453 дней спустя
Charles River Laboratories Reaffirms FY24 Outlook; Q1 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) reaffirmed its adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2024.
RTTNews
|
543 дней спустя
Charles River Laboratories Narrows FY23 Outlook Range; Q3 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) narrowed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2023.
RTTNews
|
726 дней спустя
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews
|
907 дней спустя
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss
While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews
|
1188 дней спустя
DURECT Appoints Timothy Papp As New CFO
Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews
|
1217 дней спустя
Australian Market Extends Early Losses In Mid-market
The Australian stock market is extending its early losses in mid-market trading on Tuesday, reversing the gains in the previous session, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling well below the 8,850 level, with weakness in iron ore miners, financial, energy and technology stocks partially offset by gains in gold miners and stocks.
RTTNews
|
1ч 31мин назад
Asian Markets Trade Mixed
Asian stock markets are trading mixed on Tuesday, following the mixed cues from Wall Street overnight, as traders have been reluctant to make more significant moves ahead of the release of US payroll processor ADP's report on private sector employment on Wednesday. A survey showed economic activity in the U.S. manufacturing sector contracted in October for the eighth consecutive month.
RTTNews
|
1ч 58мин назад
